World Cardiology Conference 2026

Abstract

Introduction: Arterial hypertension is present in 40–60% of adult patients with obstructive hypertrophic cardiomyopathy (OHCM); however, the clinical implications of this combination remain insufficiently investigated.

Objective: To review the pharmacological treatment strategies and the role of emerging therapeutic approaches in patients with OHCM and concomitant arterial hypertension.

Results: Patients within this cohort are generally older, have more of cardiometabolic comorbidities and greater functional impairment compared with patients with isolated OHCM. Hypertension is associated with an increased incidence of atrial fibrillation and acute cerebrovascular events. Its impact on ventricular arrhythmias, sudden cardiac death and overall mortality remains uncertain. Management of these patients is challenging, as vasodilatory antihypertensive agents may enhance left ventricular outflow tract obstruction. Beta-blockers and non-dihydropyridine calcium channel blockers are preferred. Novel agents, including cardiac myosin inhibitors and SGLT2 inhibitors, have therapeutic potential, but require further clinical evaluation..

Conclusions: The combination of OHCM and hypertension is common but remains poorly understood in terms of both diagnosis and treatment. Further research is needed to optimize therapeutic strategies for this group of patients..